NEW YORK – Exact Sciences reported after the close of the market on Thursday that its second quarter revenues rose 35 percent year over year, despite a 34 percent decrease in screening product revenues.
For the three months ended June 30, the Madison, Wisconsin-based molecular diagnostics company reported revenues of $268.9 million, up from $199.9 million a year earlier, beating the average Wall Street estimate of $228.4 million.